The biggest life sciences IPO of the year so far belongs to Legend Biotech.

The cancer drug developer was able to raise $423.8 million after pricing its shares well above the targeted price range. Legend, which has executive offices Somerset, NJ, had planned to sell 18 million shares in the range of $18 to $20 apiece. But investor interest in the company was strong enough to warrant boosting the target, and on Friday morning, Legend priced its shares at $23 each.

The biotech supplemented its IPO haul with a separate transaction. Former parent company and majority shareholder GenScript Biotech bought more… Read more »

UNDERWRITERS AND PARTNERS